AU2020294253A1

AU2020294253A1 - Nutritional Composition For Promoting Intestinal Health

Info

Publication number: AU2020294253A1
Application number: AU2020294253A
Authority: AU
Inventors: Ying AN; Lu DAI; Jufang LI; Jinzhu PANG
Original assignee: Inner Mongolia Mengniu Dairy Group Co Ltd
Current assignee: Inner Mongolia Mengniu Dairy Group Co Ltd
Priority date: 2019-12-27
Filing date: 2020-12-23
Publication date: 2021-07-15
Anticipated expiration: 2040-12-23
Also published as: NZ771554A; CN111011864A; AU2020294253B2

Abstract

The present invention relates to a nutritional composition that promotes intestinal health. Specifically, the nutritional composition contains human milk oligosaccharide and prebiotics, especially 2'-fucosyllactose (2'-FL), and galactooligosaccharide (GOS) and fructooligosaccharide (FOS) in a specific ratio. The nutritional composition can be added to food and dietary supplements to promote the maturation of intestine, enhance intestinal immunity and regulate intestinal flora.

Description

Nutritional Composition for Promoting Intestinal Health

FIELD OF THE INVENTION

[0001] The invention belongs to the field of food biotechnology. More specifically, the present invention relates to a nutritional component that promotes intestinal health, and

a food or dietary supplements containing the nutritional component and a preparation

method thereof. More specifically, the nutritional component contains human milk

oligosaccharides (HMO), galactooligosaccharides (GOS) and fructooligosaccharides

(FOS), wherein the weight ratio of GOS to FOS is about 9:1.

BACKGROUND OF THE INVENTION

[0002] Studies have shown that intestinal flora plays an important role in the full

life cycle, such as barrier function, metabolic response, nutritional effects, and the maturity

of the host's innate and adaptive immune responses. Therefore, intestinal health determines

the lifetime health.

[00031 The early colonization of intestinal flora in infants affects the incidence of

metabolic diseases in adulthood. Studies have shown that formula-fed infants and

breast-fed infants have significant differences in the composition of intestinal flora,

especially in the colonization of bifidobacteria and lactobacilli. By adding prebiotics (such

as human milk oligosaccharides) beneficial to the colonization of intestinal flora of infants

in formula milk powder is the current research hotspot.

[0004] The stage of old age is another turning point when the adult intestinal flora

produces significant changes. The physiological state of the elderly is in a declining period:

gastrointestinal motility dysfunction, decreased gastric acid secretion, degenerative

changes in the enteric nervous system, and increase-related intestinal diseases (intestinal

slow transit constipation, atrophic gastritis, etc.) may affect the composition and function

of the intestinal flora. Studies have found that diet supplemented with prebiotics can

promote the abundance of probiotic bacteria, increase the content of SCFAs to expand the feces volume , prevent the degradation of the saccharification flora, reduce the effect of decay-causing fermentation, lower the pH of the intestines and increase the compatibilization, and ultimately can improve the the intestinal environment of the elderly, promote gastrointestinal motility, increase the frequency of bowel movements, and prevent constipation. Prebiotics are ingredients that cause specific changes in the composition and/or activity of the intestinal microflora through selective fermentation, and endow the host with health. Prebiotics are not destroyed by the body's gastric acid, nor decomposed by digestive enzymes, and can directly reach the large intestine, stimulate the growth of beneficial bacteria in the intestine, indirectly inhibit the growth of harmful bacteria, and maintain the intestinal microecological balance. Fructooligosaccharide (FOS) and Galactooligosaccharide (GOS) are the earliest prebiotics used, which can improve the microbial state of the intestines, promote intestinal metabolic exercise, enhance immunity, improve fat metabolism, control weight, and promote cardiovascular health and many other effects.

[0005] As the metabolic function changes during pregnancy, the composition and abundance of the intestinal flora also change. The intestinal flora is closely related to the occurrence of pregnancy diseases, such as overweight/obesity, hypertension/hyperlipemia, diabetes, etc. Therefore, pertinent interventions on the intestinal flora of pregnant women (such as increasing the abundance of intestinal probiotics) are beneficial to improve adverse pregnancy outcomes.

[00061 Human milk oligosaccharides (HMO) are the third largest solid component in human milk, after lactose and fat. HMO consists of 3-14 monosaccharides, is linear or branched, and usually has lactoyl-N-tetraose (LNT), lactoyl-N-neotetraose (LNnT), lactoyl-N-hexaose (LNH) and lactose-N-neohexaose (LNnH) as the core structure. HMO can be extended further or undergo fucosylation and sialylation to form various HMOs (such as 2'-FL, 3'-FL, LNT, LNFP I, etc.). There are currently more than 200 types of HMOs that have been identified, including acidic and neutral oligosaccharides. They are essential for the maturation of the intestinal immune system, the integrity of the intestinal function and the colonization of microorganisms. HMO can be used as a bifidus factor to directly promote the proliferation of bifidobacteria and other probiotics, regulate the intestinal mucosal immune pathway, promote the maturation of the mucosal immune system, and indirectly improve the sensitivity of bacterial colonization, thereby regulating the number of intestinal flora. Studies have shown that oligosaccharides in human colostrum can reduce the stimulation level of pathogen-related molecular patterns on interleukin (IL)-8, IL-6, IL-1, monocyte chemoattractant protein-i and other pro-inflammatory factors in acute phase. At the same time, it can improve the expression of related cytokines for tissue repair and homeostasis. The fatty acids in human milk are significantly different from those in cow milk: about 70-75% of palmitic acid (C16:0) is esterified in the sn-2 position of the glycerol skeleton (sn-2 palmitate). This position-specific lipid has important biological functions: 1) promoting fatty acid absorption: 1,3-dioleic acid-2 palmitic acid (OPO) is hydrolyzed by pancreatic lipase into free fatty acids and sn-2 monoglycerides; the human body directly absorbs free unsaturated fatty acids and medium and short-chain fatty acids, while the lymphatic system will absorb sn-2 monoglycerides into the blood circulation; 2) relieving constipation and avoiding intestinal obstruction: the free sn-i and sn-3 palmitic acid in milk powder will undergo saponification reaction with calcium, magnesium and other minerals in the small intestine under acidic conditions to form saponated substances, which are directly excreted from the body, and can affect calcium absorption, increase stool hardness, cause constipation, and even increase the risk of intestinal obstruction; 3) promoting mineral absorption and improving immunity: improving the absorption and utilization of energy and minerals by infants, and reducing the loss of calcium, magnesium and other bone minerals and other nutrients in the body, and promoting bone development.

At the same time, studies also found that the combination of OPO and soluble dietary fiber

can help increase the number of bifidobacteria, help improve the intestinal flora of infants,

activate the immune system, and improve the immunity of infants.

[00071 Based on these, the present invention provides synergistic effects of optimal

nutrient components on intestinal health by combining the effects of human milk

oligosaccharide HMO, classic oligosaccharide combination and OPO on human intestinal

health, and focuses on promoting intestinal maturation, enhancing intestinal immunity and

regulating intestinal flora.

SUMMARY OF THE INVENTION

[00081 One of the objectives of the present invention is to provide a nutritional composition that is beneficial to intestinal health. The nutritional composition contains

2'-fucosyllactose (2'-FL) which contributes to the maturation of intestine and the

development of intestinal immune system, galactooligosaccharides (GOS) and

fructooligosaccharides (FOS) that help to regulate the intestinal flora, and optionally,

1,3-dioleoyl-2-palmitoyl glycerol (OPO) that helps to soften faeces, promote calcium

absorption and regulate the efficacy of intestinal flora.

[0009] Therefore, in one aspect, the present invention provides a nutritional

composition containing human milk oligosaccharides (HMO), galactooligosaccharides

(GOS) and fructooligosaccharides (FOS), wherein the weight ratio of GOS to FOS is

about 9:1.

[0010] In a specific embodiment of this aspect, the present invention provides the

nutritional composition, wherein the weight ratio of HMO to the sum of GOS and FOS

(about 9:1) is about 1:1 to about 1:200, preferably about 1:2 to about 1:100, more

preferably about 1:2 to about 1:30, particularly preferably about 1:5, 1:10, 1:15, 1:20, 1:25,

1:30, 1:40, 1 :60 or 1:90.

[0011] In another specific embodiment of this aspect, the present invention

provides the above nutritional composition, which contains OPO mixed oil; preferably, the

weight ratio of the HMO to OPO is about 1:1 to about 1:200, preferably about 1:2 to about

1:200, more preferably about 1:2 to about 1:80, and particularly preferably about 1:10,

1:20, 1:40, 1:60 or 1:80.

[0012] In another specific embodiment of this aspect, the present invention

provides the above nutritional composition, wherein the HMO is selected from the human

milk oligosaccharides rich in fucosyl group, such as 2'-FL, 3-FL, LNFP I, LNFP II, LNFP

III, LNFP V, LNFP VI, LNDFH I, LNDFH II, F-LNH I, F-LNH II, DF-LNH I, DF-LNH II,

DF-LNnH, DF-para-LNH, DF-para-LNnH, TF-LNH, etc., preferably 2'-FL.

[0013] In another specific embodiment of this aspect, the present invention

A provides the above nutritional composition, which contains 2'-FL, GOS, FOS and OPO, with the weight ratio of about (0.5~10):(35~40):(3.5~4.5):40, preferably

(1~10):(35~40):(3.5~4.5):40.

[0014] Another object of the present invention is to provide a food or dietary supplements that contributes to intestinal health, which contains the aforementioned

nutritional composition.

[0015] In another specific embodiment of this aspect, the present invention

provides the above food or dietary supplements, wherein the food or dietary supplements

is milk and dairy products, fermented flavor foods, beverages, chocolates, candies, baked

goods, fruit and vegetable juice foods. Preferably, the food or dietary supplements is meat,

fish, poultry and bushmeat, gravy, pickled, frozen, dried and cooked fruits and vegetables,

jelly, jam, preserves, eggs, milk and dairy products, edible oil and grease.

[0016] In another specific embodiment of this aspect, the present invention

is formula food for infants, pregnant and lactating women and middle-aged and elderly

people, raw cheese or processed cheese, milk beverage, solid dairy products, solid

beverages, ice cream.

[00171 Another object of the present invention is to provide the use of the above

nutritional composition in the preparation of food or dietary supplements, wherein the food

or dietary supplements is milk and dairy products, fermented flavor foods, beverages,

chocolates, candies, baked goods, fruit and vegetable juice foods. Preferably, the food or

dietary supplements is meat, fish, poultry and bushmeat, gravy, pickled, frozen, dried and

cooked fruits and vegetables, jelly, jam, preserves, eggs, milk and dairy products, edible

oil and grease.

[0018] In another specific embodiment of this aspect, the present invention

provides the above use, wherein the food or dietary supplements is formula food for

infants, pregnant and lactating women and middle-aged and elderly people, raw cheese or

processed cheese, milk beverage, solid dairy products, solid beverages, ice cream.

[0019] Another object of the present invention is to provide a method for preparing infant formula milk powder containing the above nutritional composition, which includes the following steps:

[0020] (1) Add the water-soluble ingredients into purified water at about 40-65°C to obtain the water-soluble raw ingredients.

[0021] Preferably, the water-soluble ingredients are desalted whey powder, skimmed milk powder, lactose, galactooligosaccharide (GOS), fructooligosaccharide (FOS), 2'-fucosyllactose (2'-FL).

[0022] (2) Heat the oil to about 40-65°C after pre-mixing to obtain fat-soluble raw ingredients.

[0023] Preferably, the oil is OPO mixed oiland mixed vegetable oil.

[0024] (3) Mix the water-soluble and fat-soluble raw ingredients and cool to about -6°C after homogenization.

[0025] Preferably, the homogenization pressure is about 100-200 bar.

[0026] (4) Add compounded vitamin and compounded mineral, stir evenly, sterilize, concentrate, spray dry, and then dry in a fluidized bed.

[00271 Preferably, the sterilization temperature is about 75-95°C, the sterilization time is about 20-90s; the concentration temperature is about 70-90°C; the inlet air temperature of spray drying is about 180-215°C, and the exhaust air temperature is about -90 °C; the temperature in the drying stages I, II and III of the fluidized bed is about -95°C, and the temperature in the stage IV is about 15-40°C.

[0028] (5) Deliver the dried base powder to the dry mixing tank through the powder conveying system, and dry mix with the functional ingredients that need to be dry mixed, to obtain infant formula milk powder.

[0029] Another object of the present invention is to provide a method for preparing formula food for middle-aged and elderly people containing the above nutritional composition, which includes the following steps:

[0030] (1) Add the water-soluble ingredients into purified water at about 40-65°C to obtain the water-soluble raw ingredients.

[0031] Preferably, the water-soluble ingredients are whole milk powder, skimmed milk powder, lactose, maltodextrin, 2'-fucosyllactose (2'-FL), fructooligosaccharide

(FOS), galactooligosaccharide (GOS).

[0032] (2) Heat the oil to about 40-65°C to obtain fat-soluble raw ingredients.

[0033] Preferably, the oil is OPO mixed oil.

[0034] (3) Mix the water-soluble and fat-soluble raw ingredients and cool to about

-6°C after homogenization.

[00351 Preferably, the homogenization pressure is about 100-200 bar.

[00361 (4) Add compounded vitamin and compounded mineral and other food additives, stir evenly, sterilize, concentrate, spray dry, and then dry in a fluidized bed.

[00371 Preferably, the other food additive is citric acid. Preferably, the sterilization

temperature is about 75-95°C, the sterilization time is about 20-90s; the concentration

temperature is about 70-90°C; the inlet air temperature of spray drying is about 180-215°C,

and the exhaust air temperature is about 70-90 °C; the temperature in the drying stages I, II

and III of the fluidized bed is about 15-95°C, and the temperature in the stage IV is about

-400 C.

[0038] (5) Deliver the dried base powder to the dry mixing tank through the

powder conveying system, and dry mix with the functional ingredients that need to be dry

mixed, to obtain formula milk powder for middle-aged and elderly people.

[0039] Another object of the present invention is to provide a method for preparing pregnancy and lactation formula food containing the above nutritional composition, which

includes the following steps:

[0040] (1) Add the water-soluble ingredients into purified water at about 40-650 C

to obtain the water-soluble raw ingredients.

[0041] Preferably, the water-soluble ingredients are whole milk powder, skimmed

milk powder, concentrated whey protein powder, lactose, galactooligosaccharide (GOS),

fructooligosaccharide (FOS), 2'-fucosyllactose (2'-FL).

[0042] (2) Heat the oil to about 40-650 C to obtain fat-soluble raw ingredients.

[0043] Preferably, the oil is OPO mixed oil.

[0044] (3) Mix the water-soluble and fat-soluble raw ingredients and cool to about

-6°C after homogenization.

[0045] Preferably, the homogenization pressure is about 100-200 bar.

[0046] (4) Add compounded vitamin and compounded mineral and other food

additives, stir evenly, sterilize, concentrate, spray dry, and then dry in a fluidized bed.

[00471 Preferably, the other food additive is citric acid. Preferably, the sterilization

-400 C.

[0048] (5) Deliver the dried base powder to the dry mixing tank through the

mixed, to obtain maternal formula milk powder.

BRIEF DESCRIPTION OF THE DRAWINGS

[0049] In order to explain the technical solution of the present invention more

clearly, the present invention will be described in detail below with reference to the

accompanying drawings. Obviously, the drawings merely illustrate some specific

embodiments of the present invention, and do not limit the present invention.

[0050] Figure 1 shows the effect of different nutritional compositions on the

relative abundance of bifidobacteria in rat intestines;

[0051] Figure 2 shows the relative content of sIgA in the intestinal contents after

intervention of different nutritional compositions;

[0052] Figure 3 shows the relative abundance of bifidobacteria in the intestines of

newborn mice fed by different infant formula milk powders;

[0053] Figure 4 shows the relative content of sIgA in the intestinal contents after

intervention of different infant formula milk powders;

[0054] Figure 5 shows the increase ratio of the relative abundance of bifidobacteria

Q in the elderly feces treated with different middle-aged and elderly formula milk powders;

[0055] Figure 6 shows the increase ratio of the relative abundance of bifidobacteria in the feces of pregnant women in the second trimester treated with different maternal formula milk powders.

EMBODIMENTS

[00561 Definition

[0057] Unless otherwise specified, all technical and scientific terms used herein have the same meaning as those commonly understood by those skilled in the art to which the present invention belongs, but in case of conflict, the definition in this specification shall prevail.

[00581 As used in the specification and claims, the singular forms "a", "an" and "the (said)" include plural forms unless the context clearly dictates otherwise.

[0059] Unless otherwise specified, the percentages (%) in this description are weight percentages (weight%).

[00601 All numerical values or expressions related to component amounts, process conditions, etc. used in the description and claims should be understood to be modified by "about" in all cases. When the term "about" refers to a quantity or a range of values, it means that the quantity or range of values referred to is an approximation within the experimental variability (or within the error of statistical experiments), so the quantity or range of values can vary within +5 of the stated quantity or range of values.

[00611 All ranges involving the same components or properties include endpoints, which can be independently combined. Since these ranges are continuous, they include every value between the minimum and maximum values. It should also be understood that any numerical range cited in this application is intended to include all sub-ranges within that range.

[0062] When the present invention is directed to physical properties such as molecular weight or chemical property ranges, all combinations and subcombinations of the ranges and specific embodiments within it should be included. The term "comprising" (and related terms such as "containing" or "contain" or "having" or "including") includes embodiments such as, for example, any combination of substances, compositions, methods or processes, which "consists of the described features" or "essentially consists of the described features."

[00631 The "and/or" used in the description and claims should be understood as the alternativee or both" of the associated components, that is, the components exist jointly in some cases and exist separately in other cases. Multiple components listed with "and/or" should be understood in the same way, that is, "one or more" associated components. In addition to the components specifically identified in the "and/or" clause, other components may optionally be present, whether related or unrelated to those specifically identified components. Therefore, as a non-limiting example, referring to "A and/or B", when used to link open ending words such as "include", in one embodiment, it can refer only to A (optionally including components other than B); in another embodiment, it can only refer to B (optionally including components other than A); in yet another embodiment, it refers to A and B (optionally including other components) and the like.

[0064] The "or" used in this description and claims should be understood as having the same meaning as the above-defined "and/or". For example, when separating items in a list, "or" or "and/or" should be interpreted as inclusive, that is, including multiple or at least one of the listed items, but also more than one, and any optional other items not listed. Only when terms clearly point to the opposite, such as "only one" or "exactly one", or "consisting of' as used in the claims, should it mean that it includes multiple or exactly one of the listed components. Generally, as used herein, the term "or" is only considered as an exclusive choice when there are exclusive antecedents such as "or", "one of', "only one" or "exactly one" (that is, one or the other but not both).

[00651 It should be understood that, unless explicitly indicated to the contrary, in any method claimed herein that includes more than one steps or actions, the order of the steps and actions of the method need not be limited to the order of the steps and actions of the method mentioned.

[00661 The abbreviations used in the present invention have the usual meanings in the fields of food, biology and chemistry.

[00671 Nutritional Composition

[00681 The nutritional composition of the present invention has (but not limited to) the following functions:

[00691 It can regulate the intestinal flora, proliferate beneficial bacteria, and inhibit harmful bacteria; it can be used as an anti-adhesive antibacterial agent to prevent pathogens from adhering to the surface of the intestinal mucosa by means of soluble decoy

11) receptors, reduce the risk of infection; regulate the response of epidermal cells and immune cells, reduce the excessive infiltration and excessive activation of mucosal leukocytes; reduce the risk of necrotizing enterocolitis, etc.. Specifically, it can exert unique functional characteristics in different populations:

[00701 1) Promote infant intestinal health: The difference in oligosaccharide structure is the main nutrient difference between cow milk and breast milk. The development of infant formula is based on cow milk. Supplementing oligosaccharides close to breast human milk can reduce the difference between infant formula and breast milk, and promote the intestinal development and health of infants fed with formula milk are closer to those of breastfeeding.

[00711 2) Promote the intestinal health of middle-aged and elderly people: Alteration of intestinal flora and decline of intestinal function are the main problems of intestinal health of middle-aged and elderly people. This nutritional composition can regulate the intestinal flora, enhance intestinal immune function, and help intestinal peristalsis and other functions to solve the intestinal health problems of middle-aged and elderly people.

[0072] 3) Promote intestinal health of pregnant women: Intestinal health during pregnancy is related to diabetes, hypertension and other diseases during pregnancy. A healthy intestinal micro-ecology is the key to healthy pregnancy. This nutritional composition helps to regulate the intestinal flora of pregnant women and prevent diarrhea and constipation, thereby solving the intestinal health problems of pregnant women.

[0073] The present invention relates to a nutritional composition that is beneficial to intestinal health, which contains 2'-fucosyllactose (2'-FL) which contributes to the maturation of intestine and the development of intestinal immune system, galactooligosaccharides (GOS) and fructooligosaccharides (FOS) that help to regulate the intestinal flora, and optionally, 1,3-dioleoyl-2-palmitoyl glycerol (OPO) that helps to soften faeces, promote calcium absorption and regulate the efficacy of intestinal flora.

[0074] It is especially important that the combination of the above-mentioned components in a specific ratio can achieve unexpected synergistic effects with respect to the respective effects of each component or the sum of the respective effects. The specific ratio is detailed below:

[00751 wherein, 2'-fucosyllactose (2'-FL) accounts for 0.1-10 parts (preferably 1-10 parts), the sum of galactooligosaccharide (GOS) and fructooligosaccharide (FOS) (GOS:FOS=1:1-15:1) accounts for 10-50 parts, 1,3-dioleoyl-2-palmitoyl glycerol (OPO) mixed oil accounts for 80-120 parts (wherein, OPO accounts for 32-48 parts).

[0076] Preferably, 2'-fucosyllactose (2'-FL) accounts for 1-10 parts, more preferably 1 part, 2 parts, 3 parts, 4 parts, 5 parts, 6 parts, 7 parts, 8 parts, 9 parts, 10 parts or any range therebetween, particularly preferably 1-2 parts, and even particularly preferably 1.5 parts.

[00771 Preferably, the ratio of galactooligosaccharide (GOS) to fructooligosaccharide (FOS) is GOS:FOS=2:1, GOS:FOS=3:1, GOS:FOS=4:1, GOS:FOS=5:1, GOS:FOS=6:1, GOS:FOS=7:1, GOS:FOS=8:1, GOS:FOS=9:1, GOS:FOS=10:1, GOS:FOS=11:1, GOS:FOS=12:1, GOS:FOS=13:1, GOS:FOS=14:1 or any range therebetween, particularly preferably GOS:FOS=8:1-10:1, and even particularly preferablyGOS:FOS=9:1.

[0078] Preferably, the sum of galactooligosaccharide (GOS) and fructooligosaccharide (FOS) accounts for 15 parts, 20 parts, 25 parts, 30 parts, 35 parts, 40 parts, 45 parts or any range therebetween, particularly preferably 35-45 parts, and even particularly preferably 40 parts.

[00791 Preferably, OPO mixed oil accounts for 50 parts, 60 parts, 70 parts, 80 parts, parts, 100 parts, 110 parts or any range therebetween, particularly preferably OPO mixed oil accounts for 90-110 parts, even particularly preferably OPO mixed oil accounts for 100 parts, wherein OPO in the OPO mixed oil accounts for 20 parts, 24 parts, 28 parts, 32 parts, 36 parts, 40 parts, 44 parts, preferably 36 parts to 44 parts, particularly preferably parts.

[0080] Food or Dietary supplements

[0081] The nutritional composition of the present invention can be added to any food or dietary supplements to prepare a food or dietary supplements with specific function of the nutritional composition of the present invention (for example, for promoting the intestinal health of infants, middle-aged and elderly, pregnant women).

[0082] For example, the food or dietary supplements that can be added with the nutritional composition of the present invention are milk and dairy products, fermented flavor foods, beverages, chocolates, candies, baked goods, fruit and vegetable juice foods. Preferably, the food or dietary supplements is meat, fish, poultry and bushmeat, gravy, pickled, frozen, dried and cooked fruits and vegetables, jelly, jam, preserves, eggs, milk and dairy products, edible oil and grease.

[0083] More specifically, the food or dietary supplements is formula food for

11) infants, pregnant women and middle-aged and elderly people, raw cheese or processed cheese, milk beverage, solid dairy products, solid beverages, or ice cream.

[0084] Specific Products and Preparation Methods Thereof

[0085] The nutritional composition of the present invention can be used to prepare food or dietary supplements, which are specifically mentioned above, especially formula foods for infants, pregnant women, and middle-aged and elderly people.

[0086] In a specific embodiment, the food or dietary supplements is infant formula milk powder, which includes the following main ingredients:

[00871 2'-fucosyllactose (2'-Fucosyllactose, 2'-FL), galactooligosaccharide (GOS), fructooligosaccharide (FOS), OPO mixed oil, skim milk powder, mixed vegetable oil, desalted whey powder, lactose, compounded mineral, and compounded vitamin.

[0088] Said OPO mixed oil is a mixed oil with 1,3-dioleoyl-2-palmitoyl glycerol as the main component. And it contains sunflower oil, coconut oil, soybean oil and linseed oil.

[0089] Said mixed vegetable oil includes sunflower oil, coconut oil, corn oil, rapeseed oil-low erucic acid and soybean oil.

[0090] Said compounded mineral comprises calcium carbonate, magnesium sulfate, sodium citrate, potassium chloride, ferrous sulfate, zinc sulfate, copper sulfate, and manganese sulfate.

[0091] Said compounded vitamin comprises vitamin A acetate powder, vitamin D3 powder, L-ascorbic acid, sodium L-ascorbate, dl-a-tocopherol acetate powder, thiamin hydrochloride, riboflavin, pyridoxine hydrochloride, cyanocobalamin, phytomenadione, folic acid, niacinamide, calcium D-pantothenate, inositol, and taurine.

[0092] Preferably, the weight ratio of each component is: 2'-fucosyllactose (2'-FL) 0.1-10 parts, galactooligosaccharide (GOS) 2-20 parts, fructooligosaccharide (FOS) 0.2-2 parts; OPO mixed oil 8-20 parts (the content of OPO is 3.2-8 parts), mixed vegetable oil 10-20 parts; skimmed milk powder 10-25 parts, desalted whey powder 35-60 parts; lactose 2-12 parts; compounded mineral 0.2-2 parts; compounded vitamin 0.05-0.5 parts.

[0093] The nutritional composition of the present invention also contains the following adjuvants in parts by weight: 0.002-0.2 parts of lutein, 0.001-0.1 parts of taurine, 0.005-0.05 parts of L-carnitine tartrate, 0.01-0.3 parts of choline chloride, and 0.001-0.1 parts of nucleotides.

[0094] In the OPO mixed oil, the weight percentages of sunflower oil, coconut oil, soybean oil and linseed oil are 30%-50%, 25%-50%, 10%-20%, 1%-10%, respectively, wherein the weight percentage of OPO contained therein is 10-4 0 %.

[0095] In the refined vegetable oil, the weight percentages of sunflower oil, coconut oil, corn oil, rapeseed oil-low erucic acid and soybean oil are 20%-50%, %-30%,,10%-20%, 10%%-20%,5%-15%, respectively.

[0096] The nucleotides include adenosine 5'-monophosphate, disodium '-inosinate, disodium 5'-guanylate, disodium 5'-uridylate, disodium 5'-cytidylate.

[00971 The weight percentages of the components contained in the compounded mineral are as follows: calcium carbonate 10%-40%, magnesium sulfate 10%-20%, sodium citrate 10%-30%, potassium chloride 15%-40%, ferrous sulfate 1%-5%, zinc sulfate 0.3%-3%, copper sulfate 0.02%-0.2%, manganese sulfate 0.005%-0.05% .

[0098] The weight percentages of the components contained in the compounded vitamin are as follows: vitamin A acetate powder 1. 2 %-3 .6 %, vitamin D3 powder 0.5%- 2 %, L-ascorbic acid 10%-3 0%, L-sodium ascorbate 10%- 2 0%, dl-a-tocopherol acetate powder 2%- 8 %, thiamine hydrochloride 0. 1 %-0.5 % , riboflavin 1%- 3 %, pyridoxine hydrochloride 0.05%-0.15%, cyanocobalamin 0.01%-0.5%, phytomenadione 0.1%-0.8%, folic acid 0. 2 %-0. 6 %, niacinamide 0.5%-1.5%, D-calcium pantothenate 0. 2 %- 2 %, inositol %- 3 0%, taurine 10%- 3 0 %.

[0099] The weight percentage of each component contained in the nucleotide is as follows: adenosine 5'-monophosphate 10%- 3 0%, disodium 5'-inosinate 2 5%- 4 5%, disodium 5'-guanylate 2%-13%, disodium 5'-uridylate 10%-34%, disodium 5'-cytidylate %-20%.

[00100] In another specific embodiment, the preparation method of the infant formula milk powder includes the following steps:

[00101] (1) Add the water-soluble ingredients into purified water at about 40-65°C to obtain the water-soluble raw ingredients.

[00102] Preferably, the water-soluble ingredients are desalted whey powder, skimmed milk powder, lactose, galactooligosaccharide (GOS), fructooligosaccharide (FOS), 2'-fucosyllactose (2'-FL).

[00103] (2) Heat the oil to about 40-65°C after pre-mixing to obtain fat-soluble raw ingredients.

[00104] Preferably, the oil is OPO mixed oil and mixed vegetable oil.

[00105] (3) Mix the water-soluble and fat-soluble raw ingredients and cool to about 0-6°C after homogenization.

1 /

[001061 Preferably, the homogenization pressure is about 100-200 bar.

[001071 (4) Add compounded vitamin and compounded mineral, stir evenly, sterilize, concentrate, spray dry, and then dry in a fluidized bed.

[00108] Preferably, the sterilization temperature is about 75-95°C, the sterilization time is about 20-90s; the concentration temperature is about 70-90°C; the inlet air temperature of spray drying is about 180-215°C, and the exhaust air temperature is about -90 °C; the temperature in the drying stages I, II and III of the fluidized bed is about -95°C, and the temperature in the stage IV is about 15-40°C.

[00109] (5) Deliver the dried base powder to the dry mixing tank through the powder conveying system, and dry mix with the functional ingredients that need to be dry mixed, to obtain infant formula milk powder.

[00110] In another specific embodiment, the food is middle-aged and elderly formula milk powder, which includes the following main ingredients: 2'-FL, galactooligosaccharide (GOS), fructooligosaccharide (FOS), OPO mixed oil, whole milk powder, skimmed milk powder, refined soybean oil, lactose, soybean phospholipid, maltodextrin, compounded vitamin, ferrous sulfate, calcium carbonate, zinc sulfate, citric acid, potassium hydroxide.

[00111] Said OPO mixed oil is a mixed oil with 1,3-dioleoyl-2-palmitoyl glycerol as the main component. And it contains sunflower oil, coconut oil, soybean oil and linseed oil.

[00112] Said compounded vitamin comprisess vitamin A acetate powder, vitamin D3 powder, L-ascorbic acid, L-sodium ascorbate and dl-a-tocopherol acetate powder.

[00113] Preferably, the content ratio of the ingredients is 2'-FL 0.001-1 parts, galactooligosaccharide (GOS) 0.05-5 parts, fructooligosaccharide (FOS) 0.001-0.1 parts, OPO mixed oil 0.5-5parts (including 0.2-2 parts of OPO), whole milk powder 20-60 parts, skimmed milk powder 20-50 parts, refined soybean oil 0-1 parts, lactose 5-20 parts, soybean phospholipid 0.01-2 parts, maltodextrin 5-20 parts, compounded vitamin 0.01-1 parts, ferrous sulfate 0.01-0.1 parts, calcium carbonate 0.5-2 parts, zinc sulfate 0.01-1 parts, citric acid 0.01-1 parts, potassium hydroxide 0.01-1 parts.

[00114] In the OPO mixed oil, the weight percentages of sunflower oil, coconut oil, soybean oil and linseed oil are 30%-50%, 25%-50%, 10%-20%, and 1%-10%, respectively, wherein the weight percentage of OPO contained therein is 10-40%.

[00115] The weight percentage of each component contained in the compounded vitamin is as follows: vitamin A acetate powder 0.1%-%, vitamin D3 powder

1 1Z

0.001%-0.1%, L-ascorbic acid 40%-80%, L-sodium ascorbate 10%-30%, dl-a-tocopherol acetate powder 5%-20%.

[00116] In another specific embodiment, the preparation method of the formula milk powder for middle-aged and elderly people includes the following steps:

[001171 (1) Add the water-soluble ingredients into purified water at about 40-65°C to obtain the water-soluble raw ingredients.

[00118] Preferably, the water-soluble ingredients are whole milk powder, skimmed milk powder, lactose, maltodextrin, 2'-fucosyllactose (2'-FL), fructooligosaccharide (FOS), galactooligosaccharide (GOS).

[00119] (2) Heat the oil to about 40-65°C to obtain fat-soluble raw ingredients.

[00120] Preferably, the oil is edible vegetable oil.

[00121] (3) Mix the water-soluble and fat-soluble raw ingredients and cool to about 0-6°C after homogenization.

[00122] Preferably, the homogenization pressure is about 100-200 bar.

[00123] (4) Add compounded vitamin and compounded mineral and other food additives, stir evenly, sterilize, concentrate, spray dry, and then dry in a fluidized bed.

[00124] Preferably, the other food additive is citric acid. Preferably, the sterilization temperature is about 75-95°C, the sterilization time is about 20-90s; the concentration temperature is about 70-90°C; the inlet air temperature of spray drying is about 180-215°C, and the exhaust air temperature is about 70-90 °C; the temperature in the drying stages I, II and III of the fluidized bed is about 15-95°C, and the temperature in the stage IV is about 15-40°C.

[00125] (5) Deliver the dried base powder to the dry mixing tank through the powder conveying system, and dry mix with the functional ingredients that need to be dry mixed, to obtain formula milk powder for middle-aged and elderly people.

[00126] In another specific embodiment, the food or dietary supplements is maternal formula milk powder, which includes the following main ingredients: 2'-FL, galactooligosaccharide (GOS), fructooligosaccharide (FOS), OPO mixed oil, whole milk, skimmed milk powder, concentrated whey protein powder, lactose, maltodextrin, white granulated sugar, refined soybean oil, soybean phospholipid, choline chloride, docosahexaenoic acid, compounded vitamin, ferrous sulfate, zinc sulfate, copper sulfate, citric acid monohydrate and potassium hydroxide.

[001271 Wherein, the OPO mixed oil is a mixed oil with 1,3-dioleoyl-2-palmitoyl glycerol as the main component. And it contains sunflower oil, coconut oil, soybean oil

1K and linseed oil.

[00128] Said compounded vitamin comprises vitamin A acetate powder, vitamin D3 powder, cyanocobalamin and folic acid.

[00129] Preferably, the content ratio of the ingredients is 2'-FL 0.001-0.1 parts, galactooligosaccharide (GOS) 0.01-1 parts, fructooligosaccharide (FOS) 0.001-0.1 parts, OPO mixed oil 0.5-5 parts (including 0.2-2 parts of OPO), whole milk 20-45 parts, skimmed milk powder 15-35 parts, concentrated whey protein powder 2-10 parts, lactose 2-10 parts, maltodextrin 10-30 parts, white granulated sugar 1-3 parts, refined soybean oil -1 parts, soybean phospholipid 0.1-1 parts, choline chloride 0.05-0.5 parts, docosahexaenoic acid 0.2-2 parts, compounded vitamin 0.01-0.3 parts, ferrous sulfate 0.01-0.1 parts, zinc sulfate 0.02-0.2, copper sulfate 0.001-0.1 parts, citric acid monohydrate 0.01-0.1 parts and potassium hydroxide 0.05-0.5 parts.

[00130] In the OPO mixed oil, the weight percentages of sunflower oil, coconut oil, soybean oil and linseed oil are 30%-50%, 25%-50%, 10%-20%, and 1%-10%, respectively, wherein the weight percentage of OPO contained therein is 10-40%.

[00131] The weight percentage of each component contained in the compounded vitamin is as follows: vitamin A acetate powder 20%-35%, vitamin D3 powder 0.02%-2%, cyanocobalamin 0.01%-1%, folic acid 40%-65%.

[00132] In another specific embodiment, the preparation method of the maternal formula milk powder includes the following steps:

[00133] (1) Add the water-soluble ingredients into purified water at about 40-65°C to obtain the water-soluble raw ingredients.

[00134] Preferably, the water-soluble ingredients are whole milk powder, skimmed milk powder, concentrated whey protein powder, lactose, galactooligosaccharide (GOS), fructooligosaccharide (FOS), 2'-fucosyllactose (2'-FL).

[00135] (2) Heat the oil to about 40-65°C to obtain fat-soluble raw ingredients.

[00136] Preferably, the oil is dible vegetable oil.

[001371 (3) Mix the water-soluble and fat-soluble raw ingredients and cool to about 0-6°C after homogenization.

[00138] Preferably, the homogenization pressure is about 100-200 bar.

[00139] (4) Add compounded vitamin and compounded mineral and other food additives, stir evenly, sterilize, concentrate, spray dry, and then dry in a fluidized bed.

[00140] Preferably, the other food additive is citric acid. Preferably, the sterilization temperature is about 75-95°C, the sterilization time is about 20-90s; the

1'7 concentration temperature is about 70-90°C; the inlet air temperature of spray drying is about 180-215°C, and the exhaust air temperature is about 70-90 °C; the temperature in the drying stages I, II and III of the fluidized bed is about 15-95°C, and the temperature in the stage IV is about 15-40°C.

[00141] (5) Deliver the dried base powder to the dry mixing tank through the powder conveying system, and dry mix with the functional ingredients that need to be dry mixed, to obtain maternal formula milk powder.

EXAMPLES

[00142] Example A of Nutritional Composition

[00143] Example Al: Nutritional Composition 1

[00144] The composition contains 2'-fucosyllactose (2'-FL) 0.15 parts, galactooligosaccharide (GOS) 3.87 parts, fructooligosaccharide (FOS) 0.43 parts. Wherein, the ratio of GOS to FOS is 9:1, and the ratio of 2'-FL to (GOS+FOS) is 1.5:43.

[00145] Example A2: Nutritional Composition 2

[00146] The composition contains 2'-fucosyllactose (2'-FL) 0.15 parts, galactooligosaccharide (GOS) 3.87 parts, fructooligosaccharide (FOS) 0.43 parts and OPO mixed oil 10 parts (including OPO 4 parts). Wherein, the ratio of GOS to FOS is 9:1, the ratio of 2'-FL to (GOS+FOS) is 1.5:43, and the ratio of 2'-FL to (GOS+FOS) to OPO is 1.5:43:40.

[001471 Example A3: Nutritional Composition 3

[00148] The composition contains 2'-fucosyllactose (2'-FL) 0.75 parts, galactooligosaccharide (GOS) 3.87 parts, fructooligosaccharide (FOS) 0.43 parts. Wherein, the ratio of GOS to FOS is 9:1, and the ratio of 2'-FL to (GOS+FOS) is 7.5:43.

[00149] Example A4: Nutritional Composition 4

[00150] The composition contains 2'-fucosyllactose (2'-FL) 0.75 parts, galactooligosaccharide (GOS) 3.87 parts, fructooligosaccharide (FOS) 0.43 parts and OPO mixed oil 10 parts (including OPO 4 parts). Wherein, the ratio of GOS to FOS is 9:1, the ratio of 2'-FL to (GOS+FOS) is 7.5:43, and the ratio of 2'-FL to (GOS+FOS) to OPO is 7.5:43:40.

[00151] Example A5: Nutritional Composition 5

[00152] The composition contains 2'-fucosyllactose (2'-FL) 0.75 parts.

1 Q

[001531 Example A6: Nutritional Composition 6

[00154] The composition contains galactooligosaccharide (GOS) 3.87 parts, fructooligosaccharide (FOS) 0.43 parts. Wherein, the ratio of GOS to FOS is 9:1.

[00155] Example A7: Nutritional Composition 7

[00156] The composition contains 2'-fucosyllactose (2'-FL) 0.05 parts, galactooligosaccharide (GOS) 3.87 parts, fructooligosaccharide (FOS) 0.43 parts. Wherein, the ratio of GOS to FOS is 9:1, and the ratio of 2'-FL to (GOS+FOS) is 0.5:43.

[001571 Example A8: Nutritional Composition 8

[00158] The composition contains 2'-fucosyllactose (2'-FL) 0.05 parts, galactooligosaccharide (GOS) 3.87 parts, fructooligosaccharide (FOS) 0.43 parts and OPO mixed oil 10 parts (including OPO 4 parts). Wherein, the ratio of GOS to FOS is 9:1, the ratio of 2'-FL to (GOS+FOS) is 0.5:43, and the ratio of 2'-FL to (GOS+FOS) to OPO is 0.5:43:40.

[00159] Method of Effect test:

[00160] In the present invention, the experimental method for evaluating the efficacy of nutritional composition on intestinal health:

[00161] In vivo experiments, SD rats were used to investigate the regulatory effects of nutritional composition on the colonization of intestinal flora, intestinal tissue morphology development and intestinal immune function.

[00162] (1) Grouping of experimental animals

[00163] Fifteen SD rats were selected and randomly assigned to different groups fed with different nutritional compositions. The addition ratios of 2'-FL, GOS, FOS and OPO in each group are shown in Table 1. They were sacrificed after 20 days of continuous feeding, and biological samples were collected for testing.

[00164] Table 1. Rat grouping and the component ratios of each nutritional composition (%)

2'-FL GOS FOS OPO

nutritional 0.15 3.87 0.43 0 composition 1

nutritional 0.15 3.87 0.43 4

1n composition 2 nutritional 0.75 3.87 0.43 0 composition 3 nutritional 0.75 3.87 0.43 4 composition 4 nutritional 0.75 0 0 0 composition 5 nutritional 0 3.87 0.43 0 composition 6 nutritional 0.05 3.87 0.43 0 composition 7 nutritional 0.05 3.87 0.43 4 composition 8

[00165] (2) Collection of biological samples:

[00166] Collect intestinal tissue and intestinal contents of suckling rats.

[001671 (3) Biological sample detection:

[00168] Intestinal flora detection: 16S rDNA is used for quantitative analysis of intestinal flora.

[00169] Intestinal development index detection: villus length and crypt depth; the number of Ki-67 nuclear antigen positive cells, enteroendocrine cells, Paneth cells and goblet cells are measured by immunofluorescence method to detect the proliferation and differentiation of intestinal epithelial cells; the intestinal barrier function is reflected by the number of intestinal epithelial tight junction protein Claudin-3 membrane localization.

[001701 Short-chain fatty acid detection: Use Gas Chromatography (GC) to detect short-chain fatty acids of the intestinal contents.

[001711 Detection of sIgA content in the intestine: Enzyme-linked immunoassay (ELISA) is used to detect the content of sIgA in the intestine.

[00172] (4) Experimental results:

[00173] In order to investigate the efficacy of the nutritional composition in the present invention, a rat model was used to investigate the effects of different nutritional compositions on the composition of intestinal flora, intestinal tissue development and intestinal immunity.

[00174] The results of the research showed that the relative abundances of Bifidobacterium in the intestines of rats among the groups fed with different nutritional compositions differed significantly at the genus level, as shown in Figure 1. Shown as Figure 1 that the relative abundances of Bifidobacterium at the genus level in the first four groups were significantly higher than those of the latter four groups. In the first 4 groups, after significant difference test, it was found that there was no significant difference between Group 1 and Group 3 (p>0.05), and there was no significant difference between Group 2 and Group 4 (p>0.05), but the relative abundances in Group 2 and Group 4 were significant higher than Group 1 and Group 3 (p<0.05). This indicates that the addition of OPO further enhances the colonization of Bifidobacterium in the intestine. The addition of high-dose 2'-FL did not contribute much to the further increase of the relative abundance of Bifidobacterium in the intestine. Considering the comprehensive cost value, when the ratio of 2'-FL to (GOS+FOS) to OPO is 1.5:43:40, and GOS:FOS is 9:1, it has a significant effect on the colonization of beneficial bacteria in intestine.

[001751 The results of different nutritional compositions on the development of intestinal tissues showed that there was no significant difference in the villi height and crypt depth of the jejunum, colon, and ileum after the intervention of different nutritional compositions (p>0.05), but there are significant differences in the proliferation and differentiation of epithelial cells and the expression of tight junction protein, and the results are shown in Table 2.

[00176] Table 2. The effects of different nutritional compositions on the

development of intestinal epithelial cells Number of positive cells per Group Group Group Group Group Group Group Group crypt 1 2 3 4 5 6 7 8

Ki-67 20b 26a 2 4 ab 26a 14c 12c 20b 18b

5-HT 1 3 bc 19a 1 5 bc 20a 10° 12c 1 4 bc 1 3 bc

MUC2 18 24a 2 2 ab 25 a 15° 16c 18b 20b

Lysozyme 16 17 18 17 18 16 16 14

Claudin-3 15° 32a 3Oa 29a 16c 14c 23b 22b

[001771 Ki-67 is a nuclear antigen associated with proliferating cells, and represents the proliferation of cells. It can be seen from Table 2 that the expression number of Ki-67 positive cells in Group 2, Group 3 and Group 4 was significantly higher than that in other groups, indicating that the intervention of nutritional composition in these three groups is beneficial to the proliferation of intestinal epithelial cells, thereby promoting intestinal development. The investigation of intestinal epithelial cell differentiation mainly includes the effects of different nutritional compositions on the differentiation of intestinal epithelial endocrine cells, intestinal epithelial goblet cells and intestinal epithelial Paneth cells. The differentiation of these three kinds of cells is mainly characterized by the number of 5-HT, MUC2 and Lysozyme positive cells. It can be seen from Table 2 that the number of lysozyme positive cells has no significant difference among the 8 groups, which indicates that the intervention of 8 nutritional compositions has no significant difference in the effect of the differentiation of intestinal epithelial Paneth cells. The number of 5-HT positive cells and MUC2 positive cells in Group 2 and Group 4 was significantly higher than that in other groups, which indicated that the intervention in Group 2 and Group 4 had a significant impact on the differentiation of intestinal epithelial endocrine cells and goblet cells. The intestinal barrier function is reflected by the number of tight junction protein Claudin-3 membrane localization in intestinal epithelial cell. Table 2 shows that the number of tight junction protein Claudin-3 membrane localization in intestinal epithelial cell was significantly higher in Group 2, Group 3 and Group 4 than that in other groups after the intervention.

[001781 To summarize, for the intestinal epithelial development (intestinal epithelial proliferation, differentiation and barrier), the nutritional intervention in Group 2 has the greatest impact on intestinal development and is most conducive to the healthy development of intestines.

[001791 The nutritional composition of the present invention includes three prebiotics, 2'-FL, GOS and FOS, which can be utilized by probiotics to produce short-chain fatty acids (SCFAs)in colon. The production of SCFAs can lower the pH of the intestine, thereby inhibiting the proliferation of harmful bacteria. At the same time, these SCFAs can directly act on the intestinal epithelial cells and help maintain the intestinal mucosal barrier function. Therefore, the comparison of the concentration of SCFAs produced can further illustrate the promoting effect of different nutritional compositions

,Y) on the healthy development of the intestine. Table 3 shows the concentration of several SCFAs after the intervention of different nutritional compositions. It can be seen from Table 3 that the concentration of total SCFAs in the first four groups has no significant difference, and is significantly higher than the latter four groups. In the first 4 groups, the concentration of acetic acid and isobutyric acid in Group 2, Group 3 and Group 4 were significantly higher than those in Group 1. On the whole, there was no significant difference in the total SCFAs produced in the intestines after the intervention of different nutritional compositions of Group 2, Group 3 and Group 4.

[00180] Table 3. The concentration of SCFAs in colon after the intervention of

different nutritional compositions ( mol/g)

Group 1 Group 2 Group Group 4 Group 5 Group 6 Group 7 Group

3 8

Acetic 4 2 . 8 9b 45.46a 45.31a 46.78a 30.76c 32.67c 32.18c 35.42c

acid

Propionic 22.53 20.79 19.95 22.67 20.38 21.9 22.50 19.98

acid

Butyric 16.91a 15.52 a 15.98a 13 . 7 9 b 10.58c 12 . 9 8b 10.01° 12 .4 7 b

acid

Isobutyric 2 5 . 5 6b 28.79a 29.96a 28.76a 2 0 .9 3 b 19 . 5 6b 2 0 . 3 8b 2 1 .6 5 b

acid

Valeric 10.24 13.45 15.32 14.97 9.76 8.47 10.34 12.29

acid

Isovaleric 9.96 10.78 9.98 9.65 9.32 10.27 10.32 10.01

acid

Total 128.09a 134.79a 136.5a 136.62a 10 1 .7 3b 10 5 . 8 5b 10 5 . 7 3b 1 11 .8 2b

SCFAs

[00181] At the same time, in order to investigate the influence of different nutritional composition interventions on intestinal immunity, the relative contents of sIgA in the intestinal contents were compared among groups. The results are shown in Figure 2.

It can be seen from the figure that the relative content of sIgA in the intestinal contents after the intervention of the nutritional composition of Group 2 was significantly higher than that of other groups (p<005).

[00182] Formula Milk Powder Example B

[00183] Example B1: Formula milk powder that improve infants' intestinal health (0-6 months old)

[00184] 1. Raw Materials

[00185] F1 Formula:

[00186] It contains skimmed milk powder 16.3%, desalted whey powder 48.49%, lactose 7.01%, mixed vegetable oil 27.5% and nutrient supplements.

[001871 The mixed vegetable oil includes: palm oil, sunflower oil, rapeseed oil, palm kernel oil, corn oil and coconut oil, which account for 35%, 27.5%, 27%, 4%, 3.5% and 3% of the total vegetable oil, respectively.

[00188] The nutrient supplements include minerals and vitamins, and specifically include: lutein 0.12%, choline chloride 0.032%, inositol 0.042%, L-carnitine tartrate 0.017%, nucleotide 0.047%, taurine 0.062%, compounded mineral 0.24% and compounded vitamin 0.14% and dry mixed nutrient blend.

[00189] The nucleotide includes 5'-cytidine monophosphate (5'-CMP) 17.56%; adenosine 5'-monophosphate (5'-AMP) 11.56%; disodium 5'-inosinate 10.44%, disodium '-guanylate 4.67% and disodium 5'-uridylate 17.56%.

[00190] The compounded mineral include ferrous sulfate 5.8%, zinc sulfate 4.32%, sodium selenite 0. 9 6 %, magnesium sulfate 5 6 .9 %, copper sulfate 0. 3 1%, manganese sulfate 0.093% and citric acid 0.77%.

[00191] The compounded vitamin include echolecalciferol 2.2%, dl-a-tocopheryl acetate 10. 4 %, phytomenadione 0. 8 2 %, thiamine hydrochloride 0.56%, riboflavin 0.11%, pyridoxine hydrochloride 0.32%, cyanocobalamin 0.95%, niacinamide 2.9%, D-biotin 0.01%, inositol 17%, folic acid 0.08%, D-calcium pantothenate 1. 9 7 %, taurine 23 .5%.

[00192] The dry mixed nutrient blend includes retinyl acetate, L-sodium ascorbate and lutein, which account for 3 .6 5%, 55.55% and 1 3 .7 % of the total dry mixed nutrient pre-blend, respectively.

[00193] This formula does not contain oligosaccharides.

[00194] F2 Formula:

[00195] It contains skimmed milk powder 16.3%, desalted whey powder 48.49%, lactose 6.13%, mixed vegetable oil 27.5% and nutrient supplements.

[00196] The mixed vegetable oil includes: palm oil, sunflower oil, rapeseed oil, palm kernel oil, corn oil and coconut oil, which account for 35%, 2 7 .5%, 2 7 %, 4%, 3 .5% and 3% of the total vegetable oil, respectively.

[001971 The nutrient supplements include oligosaccharides, minerals and vitamins etc., and specifically include galactooligosaccharide (GOS) 0.45%, fructooligosaccharide (FOS) 0.43%, lutein 0.12%, choline chloride0.032%, inositol 0.042%, L-carnitine tartrate 0.017%, nucleotide 0.047%, taurine 0.062%, compounded mineral 0.24%, compounded vitamin 0.14% and dry mixed nutrient blend.

[00198] The nucleotide includes 5'-cytidine monophosphate (5'-CMP) 17.56%; adenosine 5'-monophosphate (5'-AMP) 11.56%; disodium 5'-inosinate 10.44%, disodium '-guanylate 4.67% and disodium 5'-uridylate 17.56%.

[00199] The compounded mineral include ferrous sulfate 5.8%, zinc sulfate 4.32%, sodium selenite 0.96%, magnesium sulfate 56.9%, copper sulfate0.31%, manganese sulfate 0.093% and citric acid 0.77%.

[00200] The compounded vitamin include cholecalciferol 2.2%, dl-a-tocopheryl acetate 10. 4 %, phytomenadione 0. 8 2 %, thiamine hydrochloride 0.56%, riboflavin 0.11%, pyridoxine hydrochloride 0.32%, cyanocobalamin 0.95%, niacinamide 2.9%, D-biotin 0.01%, inositol 17%, folic acid 0.08%, D-calcium pantothenate 1. 9 7 %, taurine 23 .5%.

[00201] The dry mixed nutrient blend includes retinyl acetate, L-sodium ascorbate and lutein, which account for 3 .6 5%, 55.55% and 1 3 .7 % of the total dry mixed nutrient pre-blend, respectively.

[00202] The ratio of GOS to FOS is about 1:1.

[00203] F3 Formula:

[00204] It contains skimmed milk powder 14.5%, desalted whey powder 46.72%, lactose 6.13% and mixed vegetable oil 17.5%, OPO mixed oil 10% (including OPO 4%) and nutrient supplements.

[00205] The mixed vegetable oil includes palm oil, sunflower oil, rapeseed oil, palm kernel oil, corn oil, and coconut oil, which account for 35%, 2 7 .5%, 2 7 %, 4%, 3 .5% and 3% of the total vegetable oil, respectively.

[00206] The OPO mixed oil is composed of sunflower oil, coconut oil, soybean oil and linseed oil. Their proportions in the OPO mixed oil is 42%, 36%, 16%, 6%, respectively. Wherein, the proportion of 1,3-dioleoyl-2-palmitoyl glycerol in the mixed oil is 40%.

[00207] The nutrient supplements include oligosaccharides, minerals and vitamins etc., and specifically include 2'-FL 0.15%, galactooligosaccharide (GOS) 3.87%, fructooligosaccharide (FOS) 0.43%, lutein 0.12%, choline chloride 0.032%, inositol 0.042%, L-carnitine tartrate 0.017%, nucleotide 0.0 4 7 %, taurine 0.062%, compounded mineral 0.24%, compounded vitamin 0.14% and dry mixed nutrient blend.

[00208] The nucleotide includes 5'-cytidine monophosphate (5'-CMP) 17.56%; adenosine 5'-monophosphate (5'-AMP) 11.56%; disodium 5'-inosinate 10.44%, disodium '-guanylate 4.67% and disodium 5'-uridylate 17.56%.

[00209] The compounded mineral include: ferrous sulfate 5.8%, zinc sulfate 4.32%, sodium selenite 0.96%, magnesium sulfate 56.9%, copper sulfate0.31%, manganese sulfate 0.093% and citric acid 0.77%.

[00210] The compounded vitamin include: cholecalciferol 2.2%, dl-a-tocopheryl acetate 10. 4 %, phytomenadione 0. 8 2 %, thiamine hydrochloride 0.56%, riboflavin 0.11%, pyridoxine hydrochloride 0.32%, cyanocobalamin 0.95%, niacinamide 2.9%, D-biotin 0.01%, inositol 17%, folic acid 0.08%, D-calcium pantothenate 1. 9 7 %, taurine 23 .5%.

[00211] The dry mixed nutrient blend includes retinyl acetate, L-sodium ascorbate and lutein, which account for 3 .6 5%, 55.55% and 1 3 .7 % of the total dry mixed nutrient pre-blend, respectively.

[00212] The ratio of 2'-FL to (GOS+FOS) to OPO is about 1.5:43:40.

[00213] F4 Formula:

[00214] It contains skimmed milk powder 14.2%, desalted whey powder 46.42%, lactose 6.13%, mixed vegetable oil 17.5%, OPO mixed oil 10% (including OPO 4%) and nutrient supplements;

[00215] The mixed vegetable oil includes palm oil, sunflower oil, rapeseed oil, palm kernel oil, corn oil, and coconut oil, which account for 35%, 2 7 .5%, 2 7 %, 4%, 3 .5% and 3% of the total vegetable oil, respectively.

[00216] The OPO mixed oil is composed of sunflower oil, coconut oil, soybean oil and linseed oil. Their proportions in the OPO structured lipid mixed oil is 42%, 36%, 16%, 6%, respectively. Wherein, the proportion of 1,3-dioleoyl-2-palmitoyl glycerol in the mixed oil is 40%.

[002171 The nutrient supplements include oligosaccharides, minerals and vitamins etc., and specifically include 2'-FL 0.75%, galactooligosaccharide (GOS) 3.87%, fructooligosaccharide (FOS) 0.43%, lutein 0.12%, choline chloride 0.032%, inositol 0.0 4 2 %, L-carnitine tartrate 0.017%, nucleotide 0.0 4 7 %, taurine 0.0 6 2 %, compounded mineral 0.24%, compounded vitamin 0.14% and dry mixed nutrient blend.

[00218] The nucleotide includes 5'-cytidine monophosphate (5'-CMP) 17.56%; adenosine 5'-monophosphate (5'-AMP) 11.56%; disodium 5'-inosinate 10.44%, disodium '-guanylate 4.67% and disodium 5'-uridylate 17.56%.

[00219] The compounded mineral include: ferrous sulfate 5.8%, zinc sulfate 4.32%, sodium selenite 0. 9 6 %, magnesium sulfate 5 6 .9 %, copper sulfate 0. 3 1%, manganese sulfate 0.093% and citric acid 0.77%.

[00220] The compounded vitamin include: cholecalciferol 2.2%, dl-a-tocopheryl acetate 10.4%, phytomenadione 0.82%, thiamine hydrochloride 0.56%, riboflavin 0.11%, pyridoxine hydrochloride 0.32%, cyanocobalamin 0.95%, niacinamide 2.9%, D-biotin 0.01%, inositol 17%, folic acid 0.08%, D-calcium pantothenate 1. 9 7 %, taurine 23 .5%;

[00221] The dry mixed nutrient blend includes retinyl acetate, L-sodium ascorbate and lutein, which account for 3 .6 5%, 55.55% and 1 3 .7 % of the total dry mixed nutrient pre-blend, respectively.

[00222] The ratio of 2'-FL to (GOS+FOS) to OPO is about 7.5:43:40.

[00223] 2. Preparation Method

[00224] It is prepared by a dry and wet production process, including the following steps:

[00225] (1) Proportionally put the desalted whey powder, skim milk powder, lactose, 2'-FL, galactooligosaccharide (GOS), and fructooligosaccharide (FOS) into purified water at 60°C to obtain water-soluble raw ingredients;

[00226] (2) Proportionally pre-mix the OPO mixed oil and mixed vegetable oil and heat to 60°C to obtain the fat-soluble raw ingredients;

[002271 (3) Mix the water-soluble raw ingredients obtained in step (1) with the fat-soluble raw ingredients obtained in step (2), homogenize them at a pressure of 150 bar, and then cool to 4°C;

[00228] (4) Add the proportioned amount of compounded vitamin and compounded mineral, stir evenly, sterilize at 88°C for 35s, concentrate at 86°C, spray dry, and then dry in a fluidized bed to obtain the base powder. The inlet air temperature of spray drying is 200°C, and the exhaust air temperature is 80°C. During the drying process of the fluidized bed, the temperature in the drying stages I, II and III of the fluidized bed is 85°C, and the temperature in the stage IV of the fluidized bed is 35°C.

[00229] (5) Dry mixing the base powder obtained in step (4) with the functional ingredients containing lutein, taurine, L-carnitine tartrate, choline chloride and nucleartide to obtain the infant formula milk powder.

[00230] 3. Experimental results

[00231] In order to verify the application effect of the nutritional components 2'-FL, (GOS+FOS) and OPO in infant formula milk powder, animal experiments were conducted to investigate the effect of this nutritional composition on the intestinal health of infants. The newborn rat were selected as the research object, and 4 kinds of infant formula milk powder were used to feed (F1 formula milk powder does not contain prebiotics; F2 formula milk powder contains (GOS:FOS)=1:1; F3 formula milk powder contains 2'-FL:(GOS+FOS=9:1):OPO=1.5:43:40; F4 formula milk powder contains 2'-FL:(GOS+FOS=9:1):OPO=7.5:43:40). After 21 days of feeding, they were sacrificed, and the intestinal tissues and contents were collected for the detection of intestinal health-related indicators.

[00232] Figure 3 shows the relative abundance of Bifidobacterium in the intestines of newborn rats after the intervention with formula milk powder containing different prebiotics. It can be seen from Figure 3 that the relative abundance of Bifidobacterium in the F2, F3 and F4 groups was significantly higher than that in the Fl group (p<0.05), which indicates that the formula milk powder added with prebiotics can significantly promote the colonization of Bifidobacterium in the intestine. Among them, the relative abundance in F3 and F4 were significantly higher than that in F2 (p<0.05), indicating that the intervention of four nutritional compositions is better than the the two ordinary prebiotics. However, in the four groups intervened by the nutritional composition, there was no significant difference between F3 and F4 (p>0.05), indicating that a further increase in the relative content of 2'-FL had no significant effect on the colonization of Bifidobacterium.

[002331 The results of studies on the proliferation, differentiation and barrier function of intestinal epithelial cells after feeding with different formula milk powder are shown in Table 4. From the table, it can be seen that after the intervention of the formula milk powder in Group F3 and Group F4, the expression of Ki-67, 5-HT, MUC2 and lysozyme positive cells was significantly higher than that in the F1 and F2 groups, but there was no significant difference between the F3 and F4 groups. This indicates that the intervention of the four nutritional compositions can promote the development of intestinal epithelial cells, but the increase in the proportion of 2'-FL will not further produce a positive synergistic effect.

[00234] Table 4. The effects of different infant formula milk powder on the development of intestinal epithelial cells

Number of positive Fl F2 F3 F4

cells per crypt

Ki-67 10° 15b 26a 26a

5-HT 136 19a l9a 20a

MUC2 18 24a 2 4 ab 25a

Lysozyme 9b 1 2b 17a 17a

Claudin-3 15c 26a 32a 29a

[00235] The concentration of SCFAs in the colon of newborn rat after the intervention of different formula milk powder is different: Table 5 shows that the total SCFAs concentration of Group F3 and Group F4 are significantly higher than that of the other two groups, but the total butyric acid concentration of F3 group is higher than that of Group F4. This result indicates that the intervention of formula milk powder in Group F3 can significantly promote the production of SCFAs in the intestine.

[00236] Table 5. The concentration of SCFAs in colon after intervention of different infant formula milk powder ( mol/g)

Fl F2 F3 F4

Acetic acid 22.29c 35.35 45.46a 46.78a

Propionic acid 18.23 20.61 20.79 22.67

Butyric acid 12.48 15.79a 15.52a 13.79b

Isobutyric acid 15.32c 20.66 28.79a 28.76a

Valeric acid 10.21 13.33 13.45 14.97

Isovaleric acid 10.91 11.53 10.78 9.65

Total SCFAs 89.44a 117.27a 134.79a 136.62a

[002371 The relative content of sIgA in the intestinal contents of the newborn rat after feeding with different formula milk powder is shown in Figure 4. It can be seen from Figure 4 that the relative contents of sIgA in the F3 and F4 groups are significantly higher than those in the F1 and F2 groups. After a significant difference test, it was found that the difference was significant (p<0.05). Although there was no significant difference between the F3 and F4 groups, the average vaule within the Group F3 was slightly higher than that in Group F4. This indicates that the intervention of formula milk powder in Group F3 promote the development of intestinal immune function of newborn rat.

[00238] Based on the above experimental results, it can be seen that the infant formula powder in Group F3 which contains 2'-FL:(GOS+FOS=9:1):OPO=1.5:43:40 can significantly promote the intestinal health of the newborn rat.

[002391 Example B2: Formula milk powder that contributes to the intestinal health of the middle-aged and elderly people

[00240] 1. Raw Materials

[00241] H1 Formula:

[00242] It contains whole milk powder 41.31%, skimmed milk powder 31.06%, refined soybean oil 1%, lactose 10%, galactooligosaccharide (GOS) 0.045%, fructooligosaccharide (FOS) 0.043%, soybean phospholipid 0.2%, maltodextrin 15%, compounded vitamin 0.15%, ferrous sulfate 0.038%, calcium carbonate 1%, zinc sulfate 0.013%, citric acid 0.038%, potassium hydroxide 0.1%.

[00243] The compounded vitamin contains the following components by weight percentage: vitamin A acetate powder 0.85%, vitamin D3 powder 0.01%, L-ascorbic acid 6 2 .7 %, L-sodium ascorbate 22.28%, dl-a-tocopherol acetate powder 1 4 .1 6 %.

[00244] The ratio of GOS to FOS is about 1:1.

[00245] H2 Formula:

[00246] It contains whole milk powder 41%, skimmed milk powder 31.05%, lactose %, 2'-FL 0.015%, galactooligosaccharide (GOS) 0.387%, fructooligosaccharide (FOS) 0.043%, OPO mixed oil 1% (including OPO 0.4%), soybean phospholipid 0.2%, maltodextrin 15%, compounded vitamin 0.15%, ferrous sulfate 0.038%, calcium carbonate 1%, zinc sulfate 0.013%, citric acid 0.0 3 8 %, potassium hydroxide 0.1%.

[002471 The OPO mixed oil is composed of sunflower oil, coconut oil, soybean oil and linseed oil. Their proportions in the OPO mixed oil is 42%, 36%, 16%, 6%, respectively. Wherein, the proportion of 1,3-dioleoyl-2-palmitoyl glycerol in the mixed oil is 40%.

[00248] The compounded vitamin contains the following components by weight percentage: vitamin A acetate powder 0.85%, vitamin D3 powder 0.01%, L-ascorbic acid 6 2 .7 %, L-sodium ascorbate 2 2 .2 8 %, dl-a-tocopherol acetate powder 1 4 .1 6 %.

[00249] The ratio of 2'-FL to (GOS+FOS) to OPO is about 1.5:43:40.

[00250] H3 Formula:

[00251] It contains whole milk powder 40.94%, skimmed milk powder 31.05%, lactose 10.03%, 2'-FL 0.075%, galactooligosaccharide (GOS) 0.387%, fructooligosaccharide (FOS) 0.043%, OPO mixed oil 1% (including OPO 0.4%), soybean phospholipid 0.2%, maltodextrin 15%, compounded vitamin 0.15%, ferrous sulfate 0.0 3 8 %, calcium carbonate 1%, zinc sulfate 0.013%, citric acid 0.0 3 8 %, potassium hydroxide 0.1%.

[00252] The OPO mixed oil is composed of sunflower oil, coconut oil, soybean oil and linseed oil. Their proportions in the OPO mixed oil is 42%, 36%, 16%, 6%, respectively. Wherein, the proportion of 1,3-dioleoyl-2-palmitoyl glycerol in the mixed oil is 40%.

[00253] The compounded vitamin contains the following components by weight percentage: vitamin A acetate powder 0. 8 5%, vitamin D3 powder 0.01%, L-ascorbic acid 6 2 .7 %, L-sodium ascorbate 2 2 .2 8 %, dl-a-tocopherol acetate powder 1 4 .1 6 %.

[00254] The ratio of 2'-FL to (GOS+FOS) to OPO is 7.5:43:40.

[00255] 2. Preparation Method

[00256] (1) Put the water-soluble ingredients, i.e., whole milk powder, skimmed milk powder, lactose, maltodextrin, 2'-FL, fructooligosaccharide (FOS), galactooligosaccharide (GOS) into purified water at 60°C to obtain water-soluble raw ingredients;

[002571 (2) Heat the OPO mixed oil to 60°C to obtain fat-soluble raw ingredients;

[00258] (3) Mix water-soluble and fat-soluble raw ingredients, homogenize (at 150bar pressure) and then cool to 4°C;

[002591 (4) Add compounded vitamin, ferrous sulfate, calcium carbonate, zinc sulfate and other food additives (citric acid and potassium hydroxide), stir well and sterilize (88°C, 35s), concentrate (86°C), spray dry (inlet air temperature 200°C, exhaust air temperature 80C), then dry in a fluidized bed and spray soybean phospholipid (the temperature of stages I,II, III is 85°C, the temperature of stage IV of fluidized bed is °C).

[00260] 3. Experimental results

[00261] In order to investigate the influence of different nutritional compositions on the intestinal flora in the elderly people, in vitro experiments were used to collect 10 stool samples of healthy elderly people and mix them for cultivation. During the cultivation process, different nutritional compositions were given (HI formula milk powder contains GOS: FOS=1:1; H2 formula milk powder contains 2'-FL:(GOS+FOS=9:1):OPO=1.5:43:40; H3 formula milk powder contains 2'-FL:(GOS+FOS=9:1):OPO =7.5:43:40). The growth of Bifidobacterium in the feces of the elderly was observed after 24 hours of cultivation. The experimental results are shown in Figure 5. It can be seen from Figure 5 that the growth of Bifidobacterium in Group H2 and Group H3 was significantly higher than that of Group HI (p<0.05), and the growth in Group H3 was slightly higher than that in Group H2, but there was no significant difference between the two groups. (p>0.05). This indicates that the nutritional composition containing 2'-FL:(GOS+FOS=9:1):OPO=1.5:43:40 can contribute to the proliferation of Bifidobacterium in the intestinal tract of the elderly people.

[00262] Example B3: Formula milk powder that contributes to the intestinal health of pregnant and lying-in woman

[00263] 1. Raw Materials

[00264] W1 Formula:

[00265] It contains whole milk36.2%, skimmed milk powder 30.08%, concentrated whey protein powder 5.9%, lactose 5.8%, galactooligosaccharide (GOS) 0.04%, fructooligosaccharide (FOS) 0.036%, refined soybean oil 0.36%, maltodextrin 16.69%, white granulated sugar 2%, soybean phospholipid 0.5%, choline chloride 0.19%, docosahexaenoic acid 1. 7 %, compounded vitamin 0.25%, ferrous sulfate 0.068%, zinc sulfate 0.027%, copper sulfate 0.013%, citric acid monohydrate 0.042% and potassium hydroxide 0.1%.

[002661 The compounded vitamin contains the following components by weight percentage: vitamin A acetate powder 20%-35%, vitamin D3 powder 0.02%-2%, cyanocobalamin 0.01%-1%, folic acid 40%- 6 5 %.

[002671 The ratio of GOS to FOS is about 1:1.

[00268] W2 Formula:

[00269] It contains whole milk 36.18%, skimmed milk powder 29.19%, concentrated whey protein powder 5.9%, lactose 5.8%, 2'-FL 0.01 5 %, galactooligosaccharide (GOS) 0.387%, fructooligosaccharide (FOS) 0.043%, OPO mixed oil 1% (including OPO 0.4%), maltodextrin 16.69%, white granulated sugar 2%, soybean phospholipid 0.5%, choline chloride 0.19%, docosahexaenoic acid 1.7%, compounded vitamin 0.25%, ferrous sulfate 0.068%, zinc sulfate 0.027%, copper sulfate 0.013%, citric acid monohydrate 0.042% and potassium hydroxide 0.1%.

[002701 The OPO mixed oil is composed of sunflower oil, coconut oil, soybean oil and linseed oil. Their proportions in the OPO mixed oil is 42%, 36%, 16%, 6%, respectively. Wherein, the proportion of 1,3-dioleoyl-2-palmitoyl glycerol (OPO) in the mixed oil is 40%.

[002711 The compounded vitamin contains the following components by weight percentage: vitamin A acetate powder 20%-35%, vitamin D3 powder 0.02%-2%, cyanocobalamin 0.01%- 1%, folic acid 40%- 6 5 %.

[00272] The ratio of 2'-FL to (GOS+FOS) to OPO is about 1.5:43:40.

[00273] W3 Formula:

[00274] It contains whole milk36.18%, skimmed milk powder 29.06%, concentrated whey protein powder 5.9%, lactose 5.8%, 2'-FL 0. 0 7 5 %, galactooligosaccharide (GOS) 0.387%, fructooligosaccharide (FOS) 0.043%, OPO structured lipid mixed oil 1% (including OPO 0.4%), maltodextrin 16.69%, white granulated sugar2%, soybean phospholipid 0.5%, choline chloride 0.19%, docosahexaenoic acid 1. 7 %, compounded vitamin 0. 2 5 %, ferrous sulfate 0.0 6 8 %, zinc sulfate 0.0 2 7 %, copper sulfate 0.013%, citric acid monohydrate 0.0 4 2 % and potassium hydroxide 0.1%.

[002751 The OPO mixed oil is composed of sunflower oil, coconut oil, soybean oil and linseed oil. Their proportions in the OPO mixed oil is 42%, 36%, 16%, 6%, respectively. Wherein, the proportion of 1,3-dioleoyl-2-palmitoyl glycerol (OPO) in the mixed oil is 40%.

[00276] The compounded vitamin contains the following components by weight percentage: vitamin A acetate powder 20%-35%, vitamin D3 powder 0.02%-2%, cyanocobalamin 0.01%-1%, folic acid 40%-65%.

[002771 The ratio of 2'-FL to (GOS+FOS) to OPO is 7.5:43:40.

[00278] 2. Preparation Method

[002791 (1) Put the water-soluble ingredients, i.e., whole milk, skimmed milk powder, concentrated whey protein powder, lactose, 2'-FL, galactooligosaccharide (GOS), fructooligosaccharide (FOS), maltodextrin, white granulated sugar into purified water at -65°C to obtain water-soluble raw ingredients;

[00280] (2) Heat the OPO mixed oil to 40-65°C to obtain fat-soluble raw ingredients;

[00281] (3) Mix water-soluble and fat-soluble raw ingredients, homogenize (at 100-200bar pressure) and then cool to 0-6°C;

[00282] (4) Add compounded vitamin, ferrous sulfate, zinc sulfate, copper sulfate and other food additives (citric acid monohydrate and potassium hydroxide), stir well and sterilize (75-95°C, 20-90s), concentrate (70-90°C), spray dry (inlet air temperature 180-215°C, exhaust air temperature 70-90°C), then dry in a fluidized bed and spray soybean phospholipid (the temperature in stages I,II, III is 15-95°C, the temperature in stage IV of fluidized bed is 15-40°C).

[00283] (5) Deliver the dried base powder into the dry mixing tank through the powder conveying system, and is dry mixed with the functional ingredients, i.e. choline chloride and docosahexaenoic acid that need to be dry mixed, to obtain maternal formula milk powder.

[00284] 3. Experimental results

[00285] In order to investigate the influence of different nutritional compositions on the intestinal flora in the pregnant woman, in vitro experiments were used to collect 10 stool samples of pregnant woman in second trimester and mix them for cultivation. During the cultivation process, different nutritional compositions were given (WI formula milk powder contains GOS:FOS=1:1; W2 formula milk powder contains 2'-FL:(GOS+FOS=9:1):OPO=1.5:43:40; W3 formula milk powder contains 2'-FL:(GOS+FOS=9:1):OPO=7.5:43:40). The growth of Bifidobacterium in the feces of the pregnant woman was observed after 24 hours of cultivation. The experimental results are shown in Figure 6. It can be seen from Figure 6 that the growth of Bifidobacterium in Group W2 and Group W3 was significantly higher than that of Group W (p<0.05), and the growth in Group W3 was slightly higher than that in Group W2, but there was no significant difference between the two groups. (p>0.05). This indicates that the nutritional composition containing 2'-FL:(GOS+FOS=9:1):OPO=1.5:43:40 can contribute to the proliferation of Bifidobacterium in the intestinal tract of the pregnant woman in second trimester.

[00286] The above are only the embodiments of the present invention. It should be pointed out here that for those of ordinary skill in the art, without departing from the inventive concept of the present invention, by modifying the chemical substituents of the ligands, improvements can also be made to achieve the purpose of regulating the luminescence color and efficiency of the complex, but these all fall within the protection scope of the present invention.

Claims

CLAIMS WHAT IS CLAIMED IS:

1. A nutritional composition, which contains human milk oligosaccharide (HMO), galactooligosaccharide (GOS) and fructooligosaccharide (FOS), wherein the weight ratio of GOS to FOS is about 9:1.

2. The nutritional composition of claim 1, wherein the weight ratio of HMO to the sum of GOS and FOS with a ratio of about 9:1 is about 1:1 to about 1:200, preferably about 1:2 to about 1:100, more preferably about 1:2 to about 1:30, particularly preferably about 1:5, 1:10, 1:15, 1:20, 1:25, 1:30, 1:40, 1 :60 or 1:90.

3. The nutritional composition of claim 1 or 2, which further contains 1,3-dioleoyl-2-palmitoyl glycerol (OPO); preferably, the weight ratio of the HMO to OPO is about 1:1 to about 1:200, preferably about 1:2 to about 1:200, more preferably about 1:2 to about 1:80, and particularly preferably about 1:10, 1:20, 1:40, 1:60 or 1:80.

4. The nutritional composition of any one of claims 1-3, wherein the HMO is selected from the human milk oligosaccharides rich in fucosyl group, such as 2'-FL, 3-FL, LNFP I, LNFP II, LNFP III, LNFP V, LNFP VI, LNDFH I, LNDFH II, F-LNH I, F-LNH II, DF-LNH I, DF-LNH II, DF-LNnH, DF-para-LNH, DF-para-LNnH, TF-LNH, etc., preferably 2'-FL.

5. The nutritional composition of any one of claims 1-4, which contains 2'-FL, GOS, FOS and OPO, with the weight ratio of about (0.5-10):(35~40):(3.5~4.5):40, preferably (1~10):(35~40):(3.5~4.5):40.

6. A food or dietary supplements, which contain(s) the nutritional composition of any one of claims 1-5.

7. The food or dietary supplements of claim 6, wherein the food or dietary supplements is milk and dairy products, fermented flavor foods, beverages, chocolates, candies, baked goods, fruit and vegetable juice foods; preferably, the food or dietary supplements is meat, fish, poultry and bushmeat, gravy, pickled, frozen, dried and cooked fruits and vegetables, jelly, jam, preserves, eggs, milk and dairy products, edible oil and grease.

8. The food or dietary supplements of claim 6 or 7, wherein the food or dietary supplements is formula food for infants, pregnant and lactating women and middle-aged and elderly people, raw cheese or processed cheese, milk beverage, solid dairy products, solid beverages, or ice cream.

9. Use of the nutritional composition of any one of claims 1-5 in the manufacture of food or dietary supplements, wherein the food or dietary supplements is milk and dairy products, fermented flavor foods, beverages, chocolates, candies, baked goods, fruit and vegetable juice foods; preferably, the food or dietary supplements is meat, fish, poultry and bushmeat, gravy, pickled, frozen, dried and cooked fruits and vegetables, jelly, jam, preserves, eggs, milk and dairy products, edible oil and grease.

10. Use of claim 9, wherein the food or dietary supplements is formula food for infants, pregnant and lactating women and middle-aged and elderly people, raw cheese or processed cheese, milk beverage, solid dairy products, solid beverages, ice cream.

11. A method for preparing infant formula milk powder containing the nutritional composition of any one of claims 1-5, comprsing the following steps: (1) add the water-soluble ingredients into purified water at about 40-65°C to obtain the water-soluble raw ingredients; preferably, the water-soluble ingredients are desalted whey powder, skimmed milk powder, lactose, galactooligosaccharide (GOS), fructooligosaccharide (FOS), 2'-fucosyllactose (2'-FL); (2) heat the oil to about 40-65°C after pre-mixing to obtain fat-soluble raw ingredients; preferably, the oil is OPO mixed oil and mixed vegetable oil; (3) mix the water-soluble and fat-soluble raw ingredients and cool to about 0-6°C after homogenization; preferably, the homogenization pressure is about 100-200 bar; (4) add compounded vitamin and compounded mineral, stir evenly, sterilize, concentrate, spray dry, and then dry in a fluidized bed; preferably, the sterilization temperature is about -95°C, the sterilization time is about 20-90s; the concentration temperature is about -90°C; the inlet air temperature of spray drying is about 180-215°C, and the exhaust air temperature is about 70-90°C; the temperature in the drying stages I, II and III of the fluidized bed is about 15-95°C, and the temperature in the stage IV is about 15-40°C; (5) deliver the dried base powder to the dry mixing tank through the powder conveying system, and dry mix with the functional ingredients that need to be dry mixed, to obtain infant formula milk powder.

12. A method for preparing formula food for middle-aged and elderly people containing the nutritional composition of any one of claims 1-5, comprsing the following steps: (1) add the water-soluble ingredients into purified water at about 40-65°C to obtain the water-soluble raw ingredients; preferably, the water-soluble ingredients are whole milk powder, skimmed milk powder, lactose, maltodextrin, 2'-fucosyllactose (2'-FL), fructooligosaccharide (FOS), galactooligosaccharide (GOS); (2) heat the oil to about 40-65°C to obtain fat-soluble raw ingredients; preferably, the oil is OPO mixed oil;

(3) mix the water-soluble and fat-soluble raw ingredients and cool to about 0-6°C after

homogenization; preferably, the homogenization pressure is about 100-200 bar; (4) add compounded vitamin and compounded mineral and other food additives, stir evenly, sterilize, concentrate, spray dry, and then dry in a fluidized bed; preferably, the other food

additive is citric acid; preferably, the sterilization temperature is about 75-95°C, the

sterilization time is about 20-90s; the concentration temperature is about 70-90°C; the inlet

air temperature of spray drying is about 180-215°C, and the exhaust air temperature is about

-90°C; the temperature in the drying stages I , II andIII of the fluidized bed is about

-95°C, and the temperature in the stage IV is about 15-40°C;

(5) deliver the dried base powder to the dry mixing tank through the powder conveying system, and dry mix with the functional ingredients that need to be dry mixed, to obtain formula milk powder for middle-aged and elderly people.

13. A method for preparing maternal formula food containing the nutritional composition of any one of claims 1-5, comprsing the following steps: (1) add the water-soluble ingredients into purified water at about 40-65°C to obtain the water-soluble raw ingredients; preferably, the water-soluble ingredients are whole milk powder, skimmed milk powder, concentrated whey protein powder, lactose, galactooligosaccharide (GOS), fructooligosaccharide (FOS), 2'-fucosyllactose (2'-FL); (2) heat the oil to about 40-65°C to obtain fat-soluble raw ingredients; preferably, the oil is OPO mixed oil; (3) mix the water-soluble and fat-soluble raw ingredients and cool to about 0-6°C after homogenization; preferably, the homogenization pressure is about 100-200 bar; (4) add compounded vitamin and compounded mineral and other food additives, stir evenly, sterilize, concentrate, spray dry, and then dry in a fluidized bed; preferably, another food additive is citric acid; preferably, the sterilization temperature is about 75-95°C, the sterilization time is about 20-90s; the concentration temperature is about 70-90°C; the inlet air temperature of spray drying is about 180-215°C, and the exhaust air temperature is about

-95°C, and the temperature in the stage IV is about 15-40°C. (5) deliver the dried base powder to the dry mixing tank through the powder conveying system, and dry mix with the functional ingredients that need to be dry mixed, to obtain maternal formula milk powder.